alitretinoin and Nail-Diseases

Alitretinoin is an endogenous vitamin A derivative, 9-cis-retinoic acid. Its anti-inflammatory and immunomodulatory efficacy results from controlling leukocyte activity and cytokine production in keratinocytes. We describe three patients with severe chronic hand eczema accompanied by nail dystrophy, which was treated with alitretinoin 30 mg. Clinical evaluation at 6 months showed complete or almost complete clearing of the nail lesions. We also briefly review the literature reporting on nail dystrophy and alitretinoin treatment. There is some evidence of the clinical effect of retinoids on nail formation, owing to the presence of retinoid receptors on the nail matrix. Further studies are required to better understand the impact of alitretinoin in nail diseases. Our observation supports alitretinoin as a treatment option in retinoid-responsive dermatoses associated with nail involvement.

Topics: Adult; Alitretinoin; Anti-Inflammatory Agents; Chronic Disease; Dermatologic Agents; Eczema; Female; Hand Dermatoses; Humans; Male; Middle Aged; Nail Diseases; Treatment Outcome; Tretinoin

Treatment of nail lichen planus (LP) is difficult and an optimal therapy is lacking.. To report additional cases to the scant existing literature to learn more about therapeutic options for nail LP.. A regimen of 30 mg alitretinoin daily in 2 cases of nail LP over a period of 9 and 8 months, respectively.. In either case, nail changes showed marked improvement under oral alitretinoin therapy within 2 and 4 months, respectively. In both patients, affected nails with end-stage destructive pterygium were resistant to any previously applied therapy.. Alitretinoin is an effective treatment option for nail LP. We recommend early diagnosis of nail LP and early initiation of systemic therapy with alitretinoin to prevent the development of pterygium and permanent nail damage. However, further clinical studies are needed to establish reliable guidelines for nail LP therapy.

Topics: Alitretinoin; Antineoplastic Agents; Female; Fingers; Humans; Lichen Planus; Male; Middle Aged; Nail Diseases; Nails, Malformed; Tretinoin

Topics: Acitretin; Alitretinoin; Humans; Lichen Planus; Nail Diseases

Topics: Aged; Alitretinoin; Antibodies, Monoclonal; Antineoplastic Agents; Drug Eruptions; Humans; Lichenoid Eruptions; Male; Nail Diseases; Nivolumab; Programmed Cell Death 1 Receptor; Tretinoin

Trachyonychia can be refractory to conventional treatments including topical, intralesional or systemic corticosteroids, as well as cyclosporine and retinoids. Therefore, new treatment options are needed for recalcitrant trachyonychia.. To evaluate the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia.. A total of 21 adult patients with 210 nails affected by idiopathic recalcitrant trachyonychia were evaluated in this open-label prospective study. All patients took 30 mg of alitretinoin daily for at least 3 months. Clinical outcomes were assessed using the Physician Global Assessment (PGA) scale proposed by Park et al. (degree of roughness: 0, clear; 1, mild; 2, moderate; 3, marked; 4, severe) at baseline and 1, 3 and 6 months after treatment.. After 1, 3 and 6 months of treatment, 74.3% (123/210), 98.1% (206/210) and 99.2% (119/120) of nails showed clinical improvement, respectively; 0% (0/210), 22.9% (48/210) and 69.2% (83/120) were completely free from nail abnormalities. The mean PGA score at baseline was 3.4, decreasing significantly to 2.7, 1.3 and 0.7 at 1, 3 and 6 months following treatment, respectively.. A small number of participants and lack of a control group were limitations.. For the first time, this study evaluated the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia in adults. The results suggest that oral alitretinoin can be a good treatment option for adult patients with recalcitrant trachyonychia.

Topics: Administration, Oral; Adult; Aged; Alitretinoin; Dermatologic Agents; Female; Humans; Male; Middle Aged; Nail Diseases; Prospective Studies; Retreatment; Severity of Illness Index; Treatment Outcome; Young Adult

Topics: Administration, Oral; Adult; Alitretinoin; Antineoplastic Agents; Female; Humans; Lichen Planus; Male; Middle Aged; Nail Diseases; Nails; Retinoid X Receptors; Tretinoin

Topics: Alitretinoin; Chronic Disease; Cyclosporine; Dermatologic Agents; Drug Substitution; Eczema; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Nail Diseases; Nails, Malformed; Time Factors; Treatment Outcome; Tretinoin

Topics: Adult; Alitretinoin; Humans; Lichen Planus; Male; Nail Diseases; Treatment Outcome; Tretinoin